eligibility_summary
Eligible: advanced ovarian or pancreatic cancer after ≥1 prior line, mesothelin IHC+, measurable disease (RECIST 1.1), ECOG 2 with adequate organ function, life expectancy >3 months, women of childbearing age need negative pregnancy tests and use effective contraception for 1 year. Exclude: pregnant/lactating, uncontrolled infection (e.g., TB/HBV), prior mesothelin therapy, autoimmune disease, or inability to comply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: SY001, a PBMC-derived chimeric antigen receptor macrophage (CAR-M) cell therapy targeting mesothelin, plus tislelizumab, an anti–PD-1 monoclonal antibody checkpoint inhibitor. Mechanisms: SY001 macrophages express an anti-mesothelin CAR to recognize mesothelin+ tumor cells, enhance phagocytosis, secrete inflammatory cytokines, and present tumor antigens to T cells, remodeling the tumor microenvironment. Tislelizumab blocks PD-1 to reverse T-cell exhaustion and amplify antitumor immunity. Targets/cells: mesothelin on ovarian/pancreatic tumor cells, macrophages and T cells, PD-1/PD-L1 pathway.